News
2019
company
year
domain
Denali Therapeutics Announces First Patient Dosed In Phase 1b Study Of DNL151 For Parkinson’s Disease And Launch Of Its Engage Parkinson’s Website
Denali Therapeutics 09.04.2019
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-001 for the Treatment of Hemophilia A
Sigilon Therapeutics 08.27.2019